Biotechnology: Biological Products (No Diagnostic Substances)

Management ChangeMay 14, 2026, 04:39 PM

Ocugen Appoints Mohamed Genead as Interim CMO; Huma Qamar Departs

AI Summary

Ocugen, Inc. announced a change in its Chief Medical Officer role, effective May 8, 2026. Huma Qamar, M.D., MPH, CMI, separated from the company as CMO. Concurrently, Mohamed Genead, M.D., M.Sc., was appointed as the Acting/Interim Chief Medical Officer.

Key Highlights

Huma Qamar, M.D., MPH, CMI, separated from Ocugen as Chief Medical Officer.
The separation was effective May 8, 2026.
Mohamed Genead, M.D., M.Sc., was appointed as Acting/Interim Chief Medical Officer.
The appointment was effective May 8, 2026.

View SEC Filing

OCGN

Biotechnology: Biological Products (No Diagnostic Substances)

Ocugen, Inc.

Price Impact